Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.73 |
| ▸ | THRB | P10828 | 1/20 | 0.73 |
| ▸ | MTOR | P42345 | 1/20 | 0.73 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.73 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.73 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.73 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.63 |
| ▸ | TSHR | P16473 | 1/20 | 0.62 |
| ▸ | GLA | P06280 | 1/20 | 0.62 |
| ▸ | P2RY2 | P41231 | 3/20 | 0.59 |
| ▸ | ST6GAL1 | P15907 | 4/20 | 0.56 |
| ▸ | P2RY4 | P51582 | 1/20 | 0.53 |
| ▸ | P2RY6 | Q15077 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17304691 | 1.00 | LMNA (0.73) | LMNATHRBMTORMDM2NCOA1 | |
| SCHEMBL15338532 | 1.00 | LMNA (0.73) | LMNATHRBMTORMDM2NCOA1 | |
| SCHEMBL158513 | 1.00 | LMNA (0.73) | LMNATHRBMTORMDM2NCOA1 | |
| SCHEMBL18231346 | 1.00 | LMNA (0.73) | LMNATHRBMTORMDM2NCOA1 | |
| SCHEMBL13524621 | 1.00 | LMNA (0.73) | LMNATHRBMTORMDM2NCOA1 | |
| SCHEMBL383499 | 1.00 | LMNA (0.73) | LMNATHRBMTORMDM2NCOA1 | |
| SCHEMBL14178411 | 1.00 | LMNA (0.73) | LMNATHRBMTORMDM2NCOA1 | |
| Trifluoroacetic Acid SCHEMBL4666697 | 0.92 | LMNA (0.62) | LMNATHRBMTORMDM2NCOA1 | |
| SCHEMBL5964221 | 0.91 | LMNA (0.70) | LMNATHRBMTORMDM2NCOA1 | |
| SCHEMBL888543 | 0.90 | LMNA (0.66) | LMNATHRBMTORMDM2NCOA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9249173-B2 | Compounds and pharmaceutical compositions for the treatment of viral infections | IDENIX PHARMACEUTICALS, LLC (US) | 2016-02-02 | — | — | US | claimed |
| US-9624249-B2 | Nucleoside kinase bypass compositions and methods | MERCK SHARP & DOHME CORP. (US) | 2017-04-18 | — | — | US | disclosed |
| US-20170101431-A1 | NUCLEOSIDE DERIVATIVES FOR THE TREATMENT OF CANCER | IDENIX PHARMACEUTICALS LLC (US) | 2017-04-13 | — | — | US | disclosed |
| EP-2909223-B1 | DINUCLEOTIDE COMPOUNDS FOR HCV INFECTION | IDENIX PHARMACEUTICALS LLC (US) | 2017-03-22 | — | — | EP | disclosed |
| US-20150315221-A1 | NUCLEOSIDE KINASE BYPASS COMPOSITIONS AND METHODS | MERCK SHARP & DOHME CORP. (US) | 2015-11-05 | — | — | US | disclosed |
| WO-2014088923-A1 | NUCLEOSIDE KINASE BYPASS COMPOSITIONS AND METHODS | MERCK SHARP & DOHME CORP. (US) | 2014-06-12 | — | — | WO | disclosed |
| US-20140112886-A1 | DINUCLEOTIDE COMPOUNDS FOR HCV INFECTION | IDENIX PHARMACEUTICALS LLC | 2014-04-24 | — | — | US | disclosed |
| US-8586559-B2 | Spinal muscular atrophy (SMA) treatment via targeting of SMN2 splice site inhibitory sequences | UNIVERSITY OF MASSACHUSETTS (US) | 2013-11-19 | — | — | US | disclosed |
| US-20130028956-A1 | METHOD FOR PREVENTING OR TREATING MEMORY IMPAIRMENT AND PHARMACEUTICAL COMPOSITIONS USEFUL THEREFORE | GEORG-AUGUST-UNIVERSITAET GOETTINGEN STIFTUNG OEFFENTLICHEN RECHTS UNIVERSITAETSMEDIZIN (DE) | 2013-01-31 | — | — | US | disclosed |
| US-20120165394-A1 | SPINAL MUSCULAR ATROPHY (SMA) TREATMENT VIA TARGETING OF SMN2 SPLICE SITE INHIBITORY SEQUENCES | UNIVERSITY OF MASSACHUSETTS (US) | 2012-06-28 | — | — | US | disclosed |
| US-20100240604-A1 | PROTECTED NUCLEOTIDE ANALOGS | ALIOS BIOPHARMA, INC. (US) | 2010-09-23 | — | — | US | disclosed |
| US-7645745-B2 | Propionic Acid (2R,3R,4R,5R)-5-(4-amino-2-oxo-2H-pyrimidin-1-yl)-4-hydroxy-4-methyl-3-propionyloxy-tetrahydro-furan-2-ylmethyl ester; inhibit RNA-dependent RNA viral replication and are useful as inhibitors of HCV NS5B polymerase | ROCHE PALO ALTO LLC (US) | 2010-01-12 | — | — | US | disclosed |
| EP-1556398-B1 | NOVEL CYTARABINE MONOPHOSPHATE PRODRUGS | METABASIS THERAPEUTICS INC (US) | 2009-09-09 | — | — | EP | disclosed |
| EP-2004634-A1 | 3',5'-DI-O-ACYLATED NUCLEOSIDES FOR HCV TREATMENT | F.HOFFMANN-LA ROCHE AG (CH) | 2008-12-24 | — | — | EP | disclosed |
| WO-2007113159-A1 | 3',5'-DI-O-ACYLATED NUCLEOSIDES FOR HCV TREATMENT | F. HOFFMANN-LA ROCHE AG (CH) | 2007-10-11 | — | — | WO | disclosed |
| US-20070232562-A1 | Antiviral nucleosides | ROCHE PALO ALTO LLC | 2007-10-04 | — | — | US | disclosed |
| US-20070032448-A1 | Sugar modified nucleosides as viral replication inhibitors | RIBAPHARM INC. | 2007-02-08 | — | — | US | disclosed |
| EP-1572705-A2 | SUGAR MODIFIED NUCLEOSIDES AS VIRAL REPLICATION INHIBITORS | Ribapharm, Inc. (US) | 2005-09-14 | — | — | EP | disclosed |
| US-20040158054-A1 | Di-ribonucleotides as specific viral RNA-polymerase inhibitors for the treatment or prevention of viral infections | RIBAPHARM INC. | 2004-08-12 | — | — | US | disclosed |
| WO-2003062255-A2 | SUGAR MODIFIED NUCLEOSIDES AS VIRAL REPLICATION INHIBITORS | RIBAPHARM INC. (US) | 2003-07-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170101431-A1 | NUCLEOSIDE DERIVATIVES FOR THE TREATMENT OF CANCER | TYMP, NSUN2, PNP | LMNA 544/4885THRB 4618/4885MTOR 2063/4885 |
| US-20140112886-A1 | DINUCLEOTIDE COMPOUNDS FOR HCV INFECTION | NSUN2, NUDT1, NSUN3 | LMNA 609/4885THRB 3123/4885MTOR 2642/4885 |
| US-20070232562-A1 | Antiviral nucleosides | RNGTT, PNP, NSUN2 | LMNA 1934/4885THRB 3711/4885MTOR 1362/4885 |
| US-20150315221-A1 | NUCLEOSIDE KINASE BYPASS COMPOSITIONS AND METHODS | DCK, DTYMK, TK1 | LMNA 4073/4885THRB 2923/4885MTOR 758/4885 |
| US-20100240604-A1 | PROTECTED NUCLEOTIDE ANALOGS | PNP, NTPCR, TYMP | LMNA 1360/4885THRB 3705/4885MTOR 2721/4885 |
| US-20070032448-A1 | Sugar modified nucleosides as viral replication inhibitors | PNP, MTAP, GALE | LMNA 4188/4885THRB 4389/4885MTOR 988/4885 |
| US-20040158054-A1 | Di-ribonucleotides as specific viral RNA-polymerase inhibitors for the treatment or prevention of viral infections | POLRMT, ADAR, RNGTT | LMNA 1985/4885THRB 4225/4885MTOR 4145/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.